NextCure Inc (NXTC)
NASDAQ:NXTC
Want to see NXTC full AI Analyst Report?
NXTC Stock Chart & Stats
$13.73
-$0.05(-5.92%)
At close: 4:00 PM EST
$13.73
-$0.05(-5.92%)
Day’s Range― - ―
52-Week Range$4.10 - $15.74
Previous CloseN/A
Volume33.57K
Average Volume (3M)37.58K
Market Cap
$31.76M
Enterprise Value$7.90M
Total Cash (Recent Filing)$41.82M
Total Debt (Recent Filing)$5.15M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-21.90
Shares Outstanding3,560,410
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.64
Enterprise Value/Ebitda-0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Immuno-oncology FocusNextCure’s specialization in antibody-based immuno-oncology and tumor microenvironment biology is a durable strategic strength: a focused scientific platform can create differentiated assets, attract partnership interest, and support licensing pathways that drive long-term value independent of short-term market moves.
Extended Cash RunwayA reported runway into 1H 2027 with roughly $41.8M of expected funding provides multi-quarter visibility for clinical development. This reduces immediate refinancing pressure, allows planned trial milestones to be reached, and preserves optionality to negotiate partnerships or milestone-based financings.
Low Financial LeverageLow reported leverage and minimal debt obligations limit fixed financing costs and bankruptcy risk, preserving flexibility to fund R&D through equity, partnerships, or non-debt arrangements. This structural balance-sheet strength supports continued clinical investment without heavy interest burdens.
Bears Say
No Revenue / Persistent LossesThe company remains pre-revenue with sizable recurring losses, reflecting that commercial cash flow is not available to fund programs. Persistent unprofitability forces dependency on external capital or partner deals, raising execution risk and constraining long-term self-funded growth prospects.
Sustained Cash BurnConsistently negative operating and free cash flow near -$49.6M in 2025 signals ongoing cash consumption to advance trials. Sustained burn intensifies financing needs, limits runway without raises, and can force accelerated dilution or cutbacks if milestone funding or partnerships do not materialize.
Dilution Risk From ATM ProgramAn at-the-market offering program creates a structural avenue for equity issuance to fund operations. Reliance on ATM raises can dilute existing shareholders, reduce per-share economics of future successes, and signal persistent funding dependence that may complicate partnering or negotiating favorable deal terms.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $4.10 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $31.76M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Jul 30, 2026 which is in 84 days.
How were NextCure Inc’s earnings last quarter?
Currently, no data Available
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Overvalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 3,560,410 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NextCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.18%
12-Months-Change
Fundamentals
Return on Equity
-152.90%
Trailing 12-Months
Asset Growth
-37.65%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Technical Analysis
Ownership Overview
―
Insiders
7.90% Mutual Funds
44.77% Other Institutional Investors
42.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---